Recent national research highlights a silent cardiovascular threat that many Americans may be unaware of. A 2026 analysis of three National Institutes of Health trials found that roughly one in five adults carries a genetically‑determined level of lipoprotein(a), or Lp(a), that puts them at heightened risk for stroke, heart attack, aortic stenosis, and peripheral artery disease.
Why Lp(a) matters
Lp(a) is a cholesterol‑carrying particle that looks like low‑density lipoprotein (LDL) but includes an extra protein called apolipoprotein(a). This “sticky” protein makes Lp(a) more likely to cling to artery walls, promoting plaque buildup and interfering with the body’s ability to dissolve blood clots. The result is a potent risk amplifier for cardiovascular events.
Genetics, not lifestyle, drive the level
Unlike LDL, which can be lowered through diet, exercise, and medication, Lp(a) levels are largely set by variants in the LPA gene. Even the healthiest, most active individuals can have dangerously high Lp(a) without any clue from a standard cholesterol panel.
What the numbers show
The American College of Cardiology flags Lp(a) levels of 125 nmol/L or higher as elevated. The NIH analysis, however, identified a sharper rise in stroke and cardiac‑death risk once levels reach 175 nmol/L. Despite these findings, fewer than 1% of U.S. adults have ever been screened for high Lp(a).
Testing and early intervention
Leading medical societies—including the American College of Cardiology and the American Heart Association—now recommend that every adult receive at least one Lp(a) test in their lifetime. The test is a simple blood draw that can be ordered separately from a routine lipid panel.
Dr. Abid Husain, a cardiologist at the Boulder Longevity Institute, emphasizes the value of early knowledge: “A patient who knows that their Lp(a) is dangerously high can work with their physician to aggressively manage every other risk factor—potentially preventing a stroke at age 55.”
How doctors respond
Because there is no FDA‑approved medication that directly lowers Lp(a), some physicians hesitate to order the test. Dr. Husain counters that view, noting that high Lp(a) should prompt more aggressive targets for LDL cholesterol, blood pressure, and blood sugar.
When a patient’s Lp(a) is elevated, clinicians often turn to statins to lower overall LDL levels, which indirectly reduces the number of Lp(a) particles circulating in the bloodstream. PCSK9 inhibitors—powerful LDL‑lowering drugs—can also modestly cut Lp(a) by about 18%.
Emerging therapies
Research is underway on treatments that directly target Lp(a). The antisense therapy lepodisiran has shown up to a 94% reduction in Lp(a) in early trials, while pelacarsen dramatically lowered Lp(a) but did not yet prove a reduction in cardiovascular events. These studies underscore that lowering the marker on lab tests does not automatically translate to fewer heart attacks or strokes.
Lifestyle still matters
Although Lp(a) cannot be changed through diet or exercise, managing other risk factors remains crucial. Regular physical activity, a heart‑healthy diet, adequate sleep, weight control, and avoiding tobacco can lessen the overall cardiovascular burden and improve outcomes for those with high Lp(a).
What readers can do
Until standard cholesterol panels include Lp(a), patients should ask their physicians about ordering the test, especially if they have a family history of early heart disease or stroke. Discussing a broader cardiovascular risk assessment can help tailor preventive strategies to each individual’s genetic profile.
By bringing awareness to this hidden risk factor, the medical community hopes to empower more Americans to take proactive steps toward heart health before a serious event occurs.
Original reporting: KTVZ (Central Oregon) — read the source article.
